Clinical presentation and predictors of target vessel revascularization after drug-eluting stent implantation

Hazem Al Muradi1, Aditya Mehra, Joseph Okolo

  • 1Division of Cardiology, Rhode Island Hospital, Brown University, 593 Eddy St, Providence, RI 02903, USA.

Insights

Clinically driven target vessel revascularization (TVR) after drug-eluting stent (DES) implantation is uncommon. Disease progression, not in-stent restenosis, is the primary driver for TVR, often presenting as acute coronary syndrome.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomedical Engineering

Background:

  • Drug-eluting stent (DES) failure can lead to target vessel revascularization (TVR).
  • Mechanisms of TVR in the DES era, including restenosis, stent thrombosis, and disease progression, require further elucidation.
  • Understanding predictors and presentations of TVR post-DES is crucial for patient management.

Purpose of the Study:

  • To examine the predictors and clinical presentations of patients undergoing clinically driven TVR after DES implantation.
  • To differentiate the contributions of restenosis, stent thrombosis, and disease progression to TVR events.

Main Methods:

  • Analysis of 2691 patients with 3401 lesions treated with DES from the Dynamic Registry (2004-2006).
  • Comparison of patients with and without TVR at 2 years based on clinical, procedural, and angiographic data.
  • Multivariate analysis to identify independent predictors of TVR and target lesion revascularization (TLR).

Main Results:

  • TVR occurred in 7.2% of patients by 2 years; TLR in 3.8%.
  • Disease progression accounted for 47% of TVR events; restenosis was the cause in 86.6% of TLR.
  • Independent predictors of TVR included younger age, diabetes, graft lesion, long lesion length, and prior intervention.

Conclusions:

  • The incidence of clinically driven TVR after DES is low.
  • Disease progression is a major contributor to TVR, explaining acute coronary syndrome presentations.
  • Low rates of in-stent restenosis and significant contribution of disease progression characterize TVR in the DES era.
Abstract

Related Concept Videos

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...